Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron DA, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu H, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ.

Cancer Discov. 2017 Mar 23. pii: CD-16-1337. doi: 10.1158/2159-8290.CD-16-1337. [Epub ahead of print]

PMID:
28336552
2.

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.

PMID:
28196596
3.

Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.

Sigel CS, Guo H, Sigel KM, Zhang M, Rekhtman N, Lin O, Klimstra DS, Jungbluth AA, Tang LK.

Cancer. 2017 Mar;125(3):188-196. doi: 10.1002/cncy.21817. Epub 2017 Jan 17.

PMID:
28094897
4.

PS01.24: Clinical Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma Characterized by Next-Generation Sequencing: Topic: Medical Oncology.

Sabari J, Rudin C, Rekhtman N.

J Thorac Oncol. 2016 Nov;11(11S):S283. doi: 10.1016/j.jtho.2016.09.059. Epub 2016 Oct 28. No abstract available.

PMID:
27969491
5.

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Jakubowski CD, Plodkowski AJ, Chang JC, Rekhtman N, Iqbal A, Paik PK, Yu HA.

Clin Lung Cancer. 2017 Jan;18(1):e81-e83. doi: 10.1016/j.cllc.2016.10.001. Epub 2016 Oct 26. No abstract available.

PMID:
27863924
6.

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG.

Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.

PMID:
27825636
7.

Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society.

Roden AC, Aisner DL, Allen TC, Aubry MC, Barrios RJ, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Ge Y, Hariri LP, Lantuejoul S, Miller RA, Mino-Kenudson M, Moreira AL, Raparia K, Rekhtman N, Sholl L, Smith ML, Tsao MS, Vivero M, Yatabe Y, Yi ES.

Arch Pathol Lab Med. 2017 Mar;141(3):437-444. doi: 10.5858/arpa.2016-0459-SA. Epub 2016 Nov 7.

PMID:
27819763
8.

Cytology Specimens: A Goldmine for Molecular Testing.

Rekhtman N, Roy-Chowdhuri S.

Arch Pathol Lab Med. 2016 Nov;140(11):1189-1190. No abstract available.

PMID:
27788046
9.

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma.

Lu S, Tan KS, Kadota K, Eguchi T, Bains S, Rekhtman N, Adusumilli PS, Travis WD.

J Thorac Oncol. 2017 Feb;12(2):223-234. doi: 10.1016/j.jtho.2016.09.129. Epub 2016 Sep 28.

PMID:
27693541
10.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD.

J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30.

PMID:
27646942
11.

Optimizing Workflows and Processing of Cytologic Samples for Comprehensive Analysis by Next-Generation Sequencing: Memorial Sloan Kettering Cancer Center Experience.

Tian SK, Killian JK, Rekhtman N, Benayed R, Middha S, Ladanyi M, Lin O, Arcila ME.

Arch Pathol Lab Med. 2016 Sep 2. [Epub ahead of print]

PMID:
27588332
12.

Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.

Zakowski MF, Rekhtman N, Auger M, Booth CN, Crothers B, Ghofrani M, Khalbuss W, Laucirica R, Moriarty AT, Tabatabai ZL, Barkan GA.

Arch Pathol Lab Med. 2016 Oct;140(10):1116-20. doi: 10.5858/arpa.2015-0316-OA. Epub 2016 Aug 23.

PMID:
27552093
13.

Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society.

Raparia K, Aisner DL, Allen TC, Beasley MB, Borczuk A, Cagle PT, Capelozzi V, Dacic S, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Rekhtman N, Roden AC, Roy-Chowdhuri S, Sholl L, Smith ML, Thunnissen E, Tsao MS, Yatabe Y.

Arch Pathol Lab Med. 2016 Jul 21. [Epub ahead of print]

PMID:
27441784
14.

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.

Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM.

Clin Cancer Res. 2017 Jan 15;23(2):523-535. doi: 10.1158/1078-0432.CCR-16-1040. Epub 2016 Jul 20.

PMID:
27440269
15.

An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.

Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD, Wistuba II, Minna JD, Gazdar AF.

Clin Cancer Res. 2016 Oct 1;22(19):4880-4889. Epub 2016 Jun 28.

PMID:
27354471
16.

Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

Sholl LM, Aisner DL, Allen TC, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao M, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2016 Aug;140(8):825-9. doi: 10.5858/arpa.2016-0163-SA. Epub 2016 May 19.

PMID:
27195432
17.

Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society.

Roy-Chowdhuri S, Aisner DL, Allen TC, Beasley MB, Borczuk A, Cagle PT, Capelozzi V, Dacic S, da Cunha Santos G, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Moreira A, Raparia K, Rekhtman N, Sholl L, Thunnissen E, Tsao MS, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print]

PMID:
27081878
18.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG.

Ann Oncol. 2016 Jul;27(7):1286-91. doi: 10.1093/annonc/mdw163. Epub 2016 Apr 7.

PMID:
27056998
19.

Molecular Assessment of Multiple Pulmonary Carcinomas: An Evolving Area.

Rekhtman N.

J Thorac Oncol. 2016 Apr;11(4):e54. doi: 10.1016/j.jtho.2016.02.008. No abstract available.

PMID:
27017305
20.

Standardized terminology and nomenclature for respiratory cytology: The Papanicolaou Society of Cytopathology guidelines.

Layfield LJ, Baloch Z, Elsheikh T, Litzky L, Rekhtman N, Travis WD, Zakowski M, Zarka M, Geisinger K.

Diagn Cytopathol. 2016 May;44(5):399-409. doi: 10.1002/dc.23457. Epub 2016 Mar 15. Erratum in: Diagn Cytopathol. 2016 Aug;44(8):714. Rektman, Natasha [corrected to Rekhtman, Natasha].

PMID:
26990836

Supplemental Content

Loading ...
Support Center